Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military Considerations

被引：0
|
作者：
Nolan, Colin F. [1 ,2 ]
机构：
[1] Naval Med Readiness & Training Command San Diego, Dept Dermatol, San Diego, CA USA
[2] 34800 Bob Wilson Dr, San Diego, CA 92134 USA
来源：
CUTIS | 2022年 / 110卷 / 06期
关键词：
DOUBLE-BLIND; PLACEBO; ADOLESCENTS; ADULTS; UPADACITINIB; ABROCITINIB; EFFICACY; SAFETY;
D O I：
10.12788/cutis.0668
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Janus kinase (JAK) inhibitors represent one of the newest and most promising additions to the available treatments of atopic dermatitis (AD). Janus kinase inhibitors offer several key benefits over injectable biologics to include more predictable pharmacokinetics, nonimmunogenicity, and flexible dosing, in addition to their oral and topical bioavailability. Recommended laboratory assessments before and during treatment in addition to medication side effects may limit the scope of use in the active-duty military population and specifically within special-duty populations. In this article, we review approved and emerging JAK inhibitors for the treatment of AD as well as important considerations for both military and nonmilitary patient populations. © 2022 Quadrant Healthcom Inc.. All rights reserved.
引用
收藏
页码：316 / 320
页数：5
相关论文
共 50 条
  • [41] Risk of incident venous thromboembolism associated with atopic dermatitis and treatment with janus kinase inhibitors: A systematic review and meta-analysis
    Chi, Ching-Chi
    Chen, Tai-Li
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 428 - 429
  • [42] Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis
    Sun, Chen
    Su, Zheng
    Zeng, Yue-Ping
    INFLAMMATION RESEARCH, 2023, 72 (09) : 1861 - 1871
  • [43] Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis
    Chen Sun
    Zheng Su
    Yue-Ping Zeng
    Inflammation Research, 2023, 72 (9) : 1861 - 1871
  • [44] Comparative safety analysis of antiinterleukin-4/interleukin-13 inhibitors and Janus Kinase inhibitors in atopic dermatitis
    Bao, Aaron
    Su, Hsing-Jou
    Wan, Joy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 768 - 771
  • [45] A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council
    Haag, Carter
    Alexis, Andrew
    Aoki, Valeria
    Bissonnette, Robert
    Blauvelt, Andrew
    Chovatiya, Raj
    Cork, Michael J.
    Danby, Simon G.
    Eichenfield, Lawrence F.
    Eyerich, Kilian
    Gooderham, Melinda
    Guttman-Yassky, Emma
    Hijnen, Dirk-Jan
    Irvine, Alan D.
    Katoh, Norito
    Murrell, Dedee F.
    Leshem, Yael A.
    Levin, Adriane A.
    Vittrup, Ida
    Olydam, Jill, I
    Orfali, Raquel L.
    Paller, Amy S.
    Renert-Yuval, Yael
    Rosmarin, David
    Silverberg, Jonathan, I
    Thyssen, Jacob P.
    Stander, Sonja
    Stefanovic, Nicholas
    Todd, Gail
    Yu, JiaDe
    Simpson, Eric L.
    BRITISH JOURNAL OF DERMATOLOGY, 2024,
  • [46] The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis
    Chen, Jingsi
    Cheng, Jun
    Yang, Huan
    Tu, Wei
    Zhang, Yan
    Luo, Xiaoyan
    Wang, Hua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) : 495 - 496
  • [47] The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis
    Zhang, Lu
    Wang, Lian
    Jiang, Xian
    DERMATOLOGIC THERAPY, 2021, 34 (05)
  • [48] A review of major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors
    不详
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (04) : E69 - E69
  • [49] The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis
    Carlos Alves
    Ana Penedones
    Diogo Mendes
    Francisco Batel Marques
    European Journal of Clinical Pharmacology, 2022, 78 : 1923 - 1933
  • [50] English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis
    Saeki, Hidehisa
    Akiyama, Masashi
    Abe, Masatoshi
    Igarashi, Atsuyuki
    Imafuku, Shinichi
    Ohya, Yukihiro
    Katoh, Norito
    Kameda, Hideto
    Kabashima, Kenji
    Tsunemi, Yuichiro
    Hide, Michihiro
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2023, 50 (01): : E1 - E19
12345